Companies in the News

BlackThorn Therapeutics Launches to Develop Novel, Targeted Treatments for Neurobehavioral Disorders

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--BlackThorn Therapeutics, a clinical stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, announced that it has closed a $40 million Series A financing. The financing was led by founding investor ARCH Venture Partners and supported by Johnson & Johnson Innovation – JJDC, Inc., along with Altitude Life Science Ventures, Mercury Fund, Alexandria Real Estate Equities and an undisclosed Founded in collaboration with top research institutions and with a world-class roster of scientific advisors, BlackThorn aims to be the leading neurobehavioral health company.“Academic research in the field of ne